Molnupiravir is an antiviral medication that has gained attention for its potential use in treating COVID-19 and other viral infections.
Molnupiravir is a prodrug, which means it is metabolized in the body into its active form. The active form of Molnupiravir works by inhibiting the replication of RNA viruses. It does this by causing mutations in the viral genetic material, which can lead to errors during viral replication and ultimately reduce the ability of the virus to reproduce.
Molnupiravir was originally developed as a potential treatment for influenza. However, its broad-spectrum antiviral activity has led to investigations into its effectiveness against other RNA viruses, including coronaviruses.
Technical Parameter | Value |
---|---|
Generic Name | EIDD-2801 (2349386-89-4) |
Indication | Treatment of COVID-19 (Cat FIP Treatment) |
Country of Origin | China |
Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
Shelf Life | 2 years |
Purity | 99% |
CAS | 2349386-89-4 |
COA | Available |
Molecular Weight | 329.31 g/mol |
EIDD-2801 can inhibit the replication of a variety of RNA viruses, can improve lung function, reduce weight loss and reduce the amount of virus in the lungs. In addition to its activity against cornaviruses, in laboratory studies, EIDD-2801 also showed activity against seasonal influenza and respiratory syncytial virus.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside